Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Naz Rahman Analyst Performance

Analyst at Maxim Group

Naz Rahman is a stock analyst at Maxim Group in the medical sector, covering 10 publicly traded companies. Over the past year, Naz Rahman has issued 6 stock ratings, including buy and hold recommendations. While full access to Naz Rahman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Naz Rahman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 4 Years
Buy Recommendations
83.33% 10 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy83.3%10 ratings
Hold16.7%2 ratings
Sell0.0%0 ratings

Out of 12 total stock ratings issued by Naz Rahman at Maxim Group, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
10 companies

Naz Rahman, an analyst at Maxim Group, currently covers 10 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
100.0%

Naz Rahman of Maxim Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
60.0%
MED - DRUGS
3 companies
30.0%
MED INSTRUMENTS
1 company
10.0%

Naz Rahman's Ratings History at Maxim Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3/18/2026Upgrade$462.49$575.00Buy
NexGel, Inc. stock logo
NXGL
NexGel
3/12/2026Lower Price Target$0.96$2.00Buy
Scienture Holdings, Inc. stock logo
SCNX
Scienture
2/24/2026Initiated Coverage$0.38$1.50Buy
Novogen Limited stock logo
KZIA
Novogen
10/2/2025Boost Price Target$6.72$20.00Buy
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
9/25/2025Lower Price Target$1.90$7.00Buy
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
8/25/2025Downgrade$5.52Hold
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
4/4/2025Reiterated Rating$1.41Hold
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
4/2/2025Initiated Coverage$9.35$17.00Buy
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3/20/2025Lower Price Target$2.99$12.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2/7/2025Lower Price Target$32.56$70.00Buy